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A simple protocol for the synthesis of N-perﬂuoroacylated and N-acylated glycals of neuraminic acid,
with a secondary cyclic amine (morpholine or piperidine) at the 4α position, has been set-up, starting
from peracetylated N-acetylneuraminic acid methyl ester that undergoes, sequentially to its direct
N-transacylation followed by a C-4 amination, a β-elimination, and a selective hydrolysis of the ester
functions, without affecting the sensitive perﬂuorinated amide.
Introduction
The viral enzyme neuraminidase (NA) is a glycoprotein ident-
iﬁed as a valid target for the development of new therapies
against the inﬂuenza virus.1 In fact, NA, which is expressed at
the surface of the virus, is responsible for the viral release from
the infected cell, where the virus is bound to the terminal sialic
acid (Neu5Ac 1, Fig. 1) of host cell sialoglycoproteins.2–6 There-
fore inhibitors of NA enzymatic activity have been shown to
reduce the diffusion of the viral infection.1 Along this line, syn-
thetic efforts for the development of new NA inhibitors,7–10 led
to the clinically used Zanamivir 2 (4-deoxy-4-guanidino-
Neu5Ac2en; Relenza™),11–14 and its isostere Oseltamivir 3
(Tamiﬂu™),15 which differs by a cyclohexene in place of the
pyranosic ring. Notably, both inhibitors possess a basic substitu-
ent at position 4α, a feature that, together with the glycal struc-
ture, appears to improve the activity against NA. Actually, the
structures of these drugs were inspired by that of the 2,3-unsatu-
rated N-acetylneuraminic acid 4 (Neu5Ac2en, DANA), the ﬁrst
sialic acid glycal showing an inhibitory activity against NA
(Fig. 1).16
Similarly, glycal 5 (FANA), which differs from DANA for a
triﬂuoroacetyl in place of an acetylamido group, has shown an
improved activity in vitro against Vibrio cholerae17 and
inﬂuence NA.18 However, while many efforts have been made to
synthesize 4α-modiﬁed analogues of DANA, little attention has
been directed to the preparation of FANA congeners, which
appears unjustiﬁed as they could be equally active against NA.
Truthfully, this is possibly due to the long-standing lack of
general methods for the FANA preparation19 and to the struggle
in preparing its 4α-substituted derivatives.
These difﬁculties were only recently overcome in our labora-
tory, where the FANA and some homologues were suitably
Fig. 1 Structures of Neu5Ac acid and of its glycals.
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synthesized.20–22 Moreover, the synthesis of 4α-substituted
FANA derivatives, starting from commercial Neu5Ac 1, still rep-
resents an attractive goal since it requires some synthetic difﬁcul-
ties, such as the introduction of the glycal function and the
insertion of a substituent at the C-4α position of a N-perﬂuoroa-
cylated Neu5Ac, to be overcome. Furthermore, the presence
of a perﬂuorinated acyl amido group, which is more prone to
hydrolysis than the corresponding Neu5Ac amide,23 in their
structure poses the problem of its survival of the overall synthetic
protocol, including an expected ﬁnal hydrolytic regeneration of
the esteriﬁed functions, leading to the target free glycals. Herein
we report a synthetic strategy, which addresses and overcomes
these problems and allows the successful synthesis of glycals
6a–d and 7a–d, analogues of FANA and DANA, with a basic
substituent (piperidine or morpholine ring) at 4α position.
Results and discussion
The ﬁrst step of our initial synthetic approach was the conversion
of peracetylated Neu5Ac methyl ester 8,24 prepared from
Neu5Ac 1, into the 4α-substituted hydroxyesters 9 and 10,
adopting the Liu et al. procedure for the amination of the perace-
tylated sialic acid esters25 (Scheme 1).
We were conﬁdent that they would generate the protected
glycals 11 and 12, precursors of the desired perﬂuorinated
glycals 13a–c and 14a–c via N-transacylation of their amido
group. Selective hydrolysis of their ester functions could then
afford FANA derivatives 6a–c and 7a–c. Moreover, we con-
sidered that the glycals 11 and 12 could afford the unreported
4α-substituted DANA derivatives 6d and 7d, by simple selective
hydrolysis.
In fact, we could prepare the hydroxy esters 9 and 10 by treat-
ing the methyl ester 8 with morpholine or piperidine at 25 °C for
24 h,25 (Scheme 1). Both reactions afforded the desired α-substi-
tuted esters in high yields, moreover, by exchanging the reaction
solvent (CH3CN in place of pyridine), and increasing the reac-
tion temperature to 60 °C we noticeably shortened the reaction
time to 5 and 7 h, respectively, without affecting the yields. As
expected from the sound mechanism proposed by the authors,25
insertion of the base at the 4α-position of compound 8 occurs
with regeneration of the 2-hemiacetalyc hydroxyl in the ﬁnal
compounds 9 and 10. This, at ﬁrst, appeared as an inconvenience
for the following glycal formation that, in all previously reported
procedures, requires the activation of the 2-hydroxyl as acetate
ester, as glycosyl chloride or as thioglycoside.26,27 In fact, initial
attempts to perform the direct dehydration of 2-hydroxylated
compounds 9 and 10, afforded unsatisfactory results under
several different conditions, even those that afforded glycal 11 as
a undesired product.28
We eventually activated the anomeric hydroxyls of com-
pounds 9 and 10 by perﬂuoroacetylation with TFAA, adopting a
procedure we previously set up in our work on C-glycoside syn-
thesis promoting the elimination of anomeric hydroxyls.29–32
Thus, we performed the dehydration of compounds 9 and 10, by
acylation of their 2-hydroxy groups with TFAA, at 23 °C for
10 min, followed by treatment of the formed 2-triﬂuoroacetates
with triﬂuoroacetic acid (TFA) in CH3CN at 135 °C for 5 min.
Under these conditions compounds 11 and 12 could be systema-
tically obtained in very good repetitive yields (80% and 78%
respectively).
The structure of both glycals was assigned on the basis of
their elemental analyses and physicochemical and spectroscopic
properties. In particular the coupling constant values between the
oleﬁnic proton at C-3 and the β-proton at C-4 signals, for both
compounds (J3,4 = 2.1 and 2.4 Hz) were diagnostic for the pres-
ence of an oleﬁnic bond and of an allylic α-orientated amino
group at C-4. This assumption was also supported by the coup-
ling constant values between the β-proton at C-4 signals and the
adjacent α-proton at C-5, for both glycals (J4,5 = 8.0 and 8.1
Hz).33–35 In fact, in all known sialic acid glycals with an epi-
meric substituent at the C-4 β-position, in agreement with the
molecular geometry, the ﬁrst coupling constant has a noticeably
higher value while the second one has a lower value (J3,4 =
5.1–5.7 and J4,5 = 5.1–5.7 Hz).
35
The successful formation of the glycals 11 and 12 from the
saturated compounds 9 and 10, prompted us to attempt the direct
transformation of the normal hydroxy amides 9 and 10 into the
transacylated FANA congeners 13a–c and 14a–c, adapting our
protocol for the contemporaneous exchange of N-acyl groups
and glycal formation of sialic acid.20–22 Thus, we treated the
hydroxy amides 9 and 10 ﬁrst with the appropriate perﬂuorinated
anhydride for 10 min at room temperature, then we heated the
formed 2-perﬂuoroacylated esters in CH3CN at 135 °C.
21
However, all attempts to perform this “one pot” transformation
were quite unsuccessful as the desired N-transacylated
Scheme 1 Reagents and conditions: i, cyclic amine, MeCN, 60 °C, 5–7 h, 73–80%; ii, TFAA, MeCN, 23 °C, 10 min, then TFA, MeCN, 135 °C,
5 min, 78–80%; iii, K2CO3, MeOH–H2O (10 : 1, v/v), 23 °C, 12 h, 85–91%.
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compounds 13a–c and 14a–c could be obtained in very low
yields (10–15%), only with forced reaction conditions, i.e.
heating for 30 min with a strong excess of perﬂuorinated anhy-
drides (20 : 1). The perﬂuorinated glycals were always
accompanied by major amounts of the normal glycals 11 and 12.
Moreover, in agreement with these negative results, our attempts
to N-transacylate the glycals 11 and 12, by treatment with TFAA
in CH3CN, at 135 °C, were unsuccessful and afforded the
N-transacylated compounds 13a–c and 14a–c in poor yields,
always accompanied by the starting glycals and by a series of
unidentiﬁed compounds, also lacking of the substituent at C-4,
as showed by mass spectrometry and NMR evidences. Thus we
decided to discontinue this route and to utilize the protected
glycals 11 and 12 to prepare the free glycals 6d and 7d by
simple basic hydrolysis. Then, hypothesizing that the unsuccess-
ful N-transacylation could be due to the chemical or steric inter-
ference of the basic substituent at C-4, we decided to modify our
protocol by inverting the reaction order, ﬁrst N-transacylating the
peracetylated methyl ester 8 (Scheme 2) and then subjecting
the N-transacylated methyl esters 15a–c to the C-4 α-amination.
We were conﬁdent that this would allow to successfully obtain
the N-perﬂuoroacylated esters 16a–c and 17a–c, as their direct
C-4 α-amination should proceed well, similarly to that of
the acetate 8. In fact, we could satisfactory prepare the saturated
N-transacylated esters 15a–c, using perﬂuorinated anhydrides, in
the presence of Et3N,
22 which avoids losing the 2-acetoxy group,
essential for the subsequent 4α amination.
We eventually performed the reaction treating esters 15a–c
with morpholine or piperidine, in pyridine (at 25 °C for 24 h), or
in CH3CN (at 60 °C for 5–7 h). The reaction works well in all
cases and affords the desired hydroxy compounds 16a–c and
17a–c in high yields (ranging from 71% to 82%). The hydroxy
compounds were then dehydrated, using the TFAA activation
and the acid treatment, as described before, affording the corre-
sponding glycals 13a–c and 14a–c in very satisfactory yields
(ranging from 77% to 82%), with the correct physico-chemical
properties. In particular, 1H NMR spectra were nearly superim-
posable to those of the acetylated compounds, and, as expected,
they differed by the lack of the acyl group proton and the NH
proton signals that, in all perﬂuorinated compounds, resonate at
lower ﬁelds (6.64–7.09 ppm in place of 5.35–5.72 ppm). Also in
these compounds, the coupling constants values of β-proton at
C-4 were diagnostic for an α-stereochemistry of the amino
group. Finally, in the 13C NMR spectra, the carbon atom of the
amidic carbonyl group of all perﬂuorinated congeners resonates
at higher ﬁelds (157.5–158.5 ppm) than those of the acetylated
congeners (170.0–171.0 ppm).
At this point, to obtain the free glycals 6a–c and 7a–c, we had
to solve the problem of the selective regeneration of the car-
boxylic and hydroxylic functions of the protected glycals 13a–c
and 14a–c, retaining their ﬂuorinated amido groups. Some basic
hydrolyic conditions were inefﬁcient (NaHCO3, Zn(CH3COO)2,
or Na3PO4, in aqueous methanol) or not selective (LiOH,
Li2CO3, tetramethylguanidine or Cs2CO3, in aqueous methanol),
while the use of K2CO3, in aqueous methanol, afforded the
correct ﬁnal perﬂuorinated glycals 6b–c and 7b–c, in very good
yields (80–90%), but caused an unselective hydrolysis of the
glycal 13a, affording a complex mixture of compounds.
Hydrolysis with aqueous NH3 in methanol caused the selective
regeneration of the alcoholic functions, but transformed the
sialic acid esters into the corresponding amides. Finally,
we obtained the free acidic glycals 6a–c and 7a–c, performing
the hydrolysis with Et3N, in aqueous methanol, at 23 °C for
12 h. The reaction is slow, but allows all the perﬂuoroacylated
glycals 6a–c and 7a–c to be prepared in good yields and with
the expected physicochemical properties. In particular the survi-
val of the perﬂuorinated acyl groups in their molecule was
evident from the chemical shift position of their carbonyl carbon
in the 13C-NMR spectra and from the inspection of their coup-
ling constants with the ﬂuorine atoms at the respective α-carbons
that are easily identiﬁable in the spectra.
The obtained glycals 6a–d and 7a–d were then inspected for
their possible inhibitory action on Vibrio cholerae sialidase
(Table 1). Assays were conducted using methods previously
reported from our department.36,37
The data for inhibition, obtained for all the 4α-amino substi-
tuted derivatives, compared with those obtained for the parent
Scheme 2 Reagents and conditions: i, TFAA, Et3N, MeCN, 135 °C, 5 min, 81–89%; ii, cyclic amine, MeCN, 60 °C, 5–7 h, 71–82%; iii, TFAA,
MeCN, 23 °C, 10 min, then TFA, MeCN, 135 °C, 5 min, 77–82%; iv, Et3N, MeOH–H2O (2 : 1, v/v), 23 °C, 12 h, 84–94%.
Table 1 Inhibition of the sialidase from Vibrio cholerae by DANA,
FANA and the analogues 6a–d and 7a–d
Compound Ki
a (M)
DANA 2.1 ± 0.027 × 10−5
FANA 1.6 ± 0.052 × 10−6
6d 1.2 ± 0.82 × 10−3
7d 1.4 ± 0.96 × 10−3
6a 1.4 ± 0.10 × 10−4
6b 1.5 ± 0.10 × 10−4
6c 1.4 ± 0.12 × 10−4
7a 4.2 ± 0.35 × 10−4
7b 4.6 ± 0.15 × 10−4
7c 4.4 ± 0.10 × 10−4
a Each value represents the mean ± standard deviation of two or three
independent experiments carried out in triplicate.
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DANA and FANA congeners, that are in good agreement with
those reported,17 show that none of the new compounds are as
effective as the parent glycal. In fact, in all cases a signiﬁcant
decrease of the anti sialidase activity is observed.
Moreover, we also performed an in vitro antiviral screening
assay using inﬂuenza A viruses H1N1 (ATCC: VR1520) and
H3N2 (ATCC: VR544) adopting a well proven method38,39 to
screen drug candidates for their potential antiviral activities.
In all cases, no positive activity was observed, and the viral
replication was found to be unchanged in the presence of all
tested compounds. These results suggest that the introduction of
a 4α-cyclic amino substituent signiﬁcantly reduces the anti-NA
and the antiviral activities of 5-acylated neuraminic acid glycals,
evidence that must be considered in programming the synthesis
of new possible NA inhibitors.
Conclusions
In our work we demonstrated that the challenging synthesis of
normal and perﬂuorinated glycals of Neu5Ac, bonding a cyclic
secondary amine at the 4α position, can be efﬁciently performed
using a simple procedure which appears general in scope. At the
same time, we have set-up a simple procedure, of general utility,
for the hydrolysis of acetates and methyl esters of Neu5Ac 1 in
the presence of a labile triﬂuoroacylated amido groups. Unfortu-
nately, a biological screening of the anti NA and anti inﬂuenza A
viruses activity of the synthesized glycals, showed that no one of
them is a possible candidate for additional studies. This negative
result is however useful to programme future synthesis of NA
inhibitors.25
Experimental
General information
Melting points are uncorrected. Nuclear magnetic resonance
spectra were recorded at 298 K operating at 500.13 MHz for 1H
and 125.76 MHz for 13C. Chemical shifts are reported in parts
per million (ppm, δ units), and in CDCl3 are relative to CDCl3
signal (ﬁxed at 7.26 ppm for 1H and at 77.0 ppm for 13C
spectra). In D2O spectra, chemical shifts are relative to D2O,
referenced to t-BuOH as internal standards (signal ﬁxed at
1.24 ppm for 1H and at 30.29 ppm for 13C spectra). Proton and
carbon assignments were established, if necessary, with 1H-1H
and 1H-13C correlated NMR experiments. 1H NMR data are
tabulated in the following order: number of protons, multiplicity
(s, singlet; d, doublet; t, triplet, t app, apparent triplet, br s, broad
singlet; m, multiplet), coupling constant(s) in hertz, assignment
of proton(s). Optical rotations were taken on a polarimeter
equipped with a 1 dm tube; [α]D values are given in 10
−1 deg
cm2 g−1 and the concentrations are given in g/100 mL. Mass
spectrometry was performed using a quadrupole ion trap mass
spectrometer equipped with an electrospray (ESI) ion source.
The spectra were collected in continuous ﬂow mode by connect-
ing the infusion pump directly to the ESI source. Solutions of
compounds were infused at a ﬂow rate of 5 μL min−1. The spray
voltage was set at 5.0 kV in the positive and at 4.5 kV in the
negative ion mode with a capillary temperature of 220 °C. Full-
scan mass spectra were recorded by scanning a m/z range of
100–2000. All reactions were monitored by thin-layer chromato-
graphy (TLC) carried out on 0.25 mm E. Merck silica gel plates
(60F 254) using UV light, 50% sulfuric acid or 0.2% ninhydrin
in ethanol, and heat as developing agents. Work-up refers to suc-
cessive washing of the organic layer with an ice cold aqueous
NaHCO3 saturated solution and water, drying over Na2SO4 and
evaporation of the solvent under reduced pressure. Rapid chrom-
atography was performed with normal phase silica gel.40 Vibrio
cholerae neuraminidsase was from Sigma Aldrich (N7885, 1–5
units per mg protein). Inﬂuenza A viruses H1N1 (ATCC:
VR1520) and H3N2 (ATCC: VR544) were kindly provided by
Prof. Fabrizio Pregliasco, from Milan University.
Methyl 5-acetamido-4-(morpholin-4-yl)-7,8,9-tri-O-acetyl-3,4,5-
trideoxy-D-glycero-β-D-galacto-non-2-ulopyranosidonate (9). The
ester 8 (213 mg, 0.40 mmol) and morpholine (0.35 mL,
4.0 mmol) were reacted in pyridine, according to the procedure
reported by Liu et al.,25 to afford the title compound 9, as a
white solid (168 mg, 81%): m.p. 153–155 °C; [α]20D + 26.6 (c 1
in CHCl3); (Found: C, 50.88; H, 6.58; N, 5.60; Calc. for:
C22H34N2O12 C, 50.96; H, 6.61; N, 5.40%);
1H NMR (CDCl3) δ
5.35 (1H, dd, J7,8 = 6.1, J7,6 = 2.1 Hz, 7-H), 5.34–5.26 (1H, br
s, N–H), 5.23–5.17 (1H, m, 8-H), 4.66 (1H, dd, J9a,9b = 12.3,
J9a,8 = 2.0 Hz, 9a-H), 5.29 (1H, br s, OH), 4.13–4.06 (2H, over-
lapping, 5-H and 6-H), 3.99 (1H, dd, J9b,9a = 12.3, J9b,8 = 7.5
Hz, 9b-H), 3.85 (3H, s, COOCH3), 3.66–3.52 (4H, overlapping,
N(CH2CH2)2O), 2.92 (1H, br s, 4-H), 2.68–2.63 (2H, overlap-
ping, N(CH2CH2)2O), 2.44–2.25 (2H, overlapping, N
(CH2CH2)2O), 2.11 (3H, s, CH3COO), 2.06 (3H, s, CH3COO),
2.04–1.98 (5H, overlapping, CH3COO, 3a-H and 3b-H), 1.94
(3H, s, CH3COO);
13C NMR (CDCl3) δ 170.6, 170.5, 170.4,
170.2 (4C, 3XCH3COO and NHCOCH3), 169.8 (C-1), 95.1
(C-2), 72.3 (C-6), 71.3 (C-8), 68.6 (C-7), 67.5 (2C, N
(CH2CH2)2O), 62.8 (C-9), 61.6 (C-4), 53.4 (COOCH3), 48.6
(2C, N(CH2CH2)2O), 46.3 (C-5), 29.5 (C-3), 23.2 (NHCOCH3),
20.9, 20.8, 20.7 (3C, 3XCH3COO); MS (ESI positive) m/z 518.9
[M + H]+, 541.1, [M + Na]+, 1058.8 [2M + Na]+.
An α-aminated compound 9, with correct elemental analyses
and physico-chemical properties superimposable to that above
described was also obtained in 80% yields when the reaction
was performed in CH3CN (4 mL), heating at 60 °C for 5 h.
Methyl 5-acetamido-4-(piperidin-1-yl)-7,8,9-tri-O-acetyl-3,4,5-
trideoxy-D-glycero-β-D-galacto-non-2-ulopyranosidonate (10).
The ester 8 (362 mg, 0.68 mmol) and piperidine (0.68 mL,
6.8 mmol) were reacted in pyridine, according to the procedure
reported by Liu et al.,25 to afford the title compound 10, as a
white solid (270 mg, 76%): m.p. 132–133 °C; [α]20D + 20.3 (c 1
in CHCl3); (Found: C, 53.14; H, 6.93; N, 5.32; Calc. for:
C23H36N2O11 C, 53.48; H, 7.02; N, 5.42%);
1H NMR (CDCl3) δ
5.38 (1H, d, JNH,5 = 9.9 Hz, N–H), 5.32 (1H, br d, J7,8 = 6.3 Hz,
7-H), 5.24–5.20 (1H, m, 8-H), 4.43 (1H, br d, J9a,9b = 12.2 Hz,
9a-H), 4.14–4.08 (2H, overlapping, OH and 5-H), 4.03 (1H, br
d, J6,5 = 10.0 Hz, 6-H), 4.00 (1H, dd, J9b,9a = 12.2, J9b,8 = 7.3
Hz, 9b-H), 3.85 (3H, s, COOCH3), 3.02–2.97 (1H, m, 4-H),
2.67–2.59 (2H, overlapping, N(CH2CH2)2CH2), 2.34–2.26
(2H, overlapping, N(CH2CH2)2CH2), 2.10 (3H, s, CH3COO),
2.04 (3H, s, CH3COO), 2.02–1.95 (5H, overlapping, CH3COO,
3a-H and 3b-H), 1.95 (3H, s, CH3CONH), 1.54–1.31
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(6H, overlapping, N(CH2CH2)2CH2);
13C NMR (CDCl3) δ
170.7, 170.6, 170.5, 170.4 (4C, 3XCH3COO and NHCOCH3),
170.0 (C-1), 95.3 (C-2), 72.7 (C-6), 71.4 (C-8), 68.7 (C-7), 62.9
(C-9), 61.8 (C-4), 53.2 (COOCH3), 49.5 (2C, N
(CH2CH2)2CH2), 46.8 (C-5), 29.5 (C-3), 26.5 (2C, N
(CH2CH2)2CH2), 24.6 (1C, N(CH2CH2)2CH2), 23.2
(NHCOCH3), 21.0, 20.9, 20.8 (3C, 3XCH3COO); MS (ESI
positive) m/z 517.1 [M + H]+, 539.1, [M + Na]+, 1054.8
[2M + Na]+. An α-aminated compound 10, with correct elemen-
tal analyses and physico-chemical properties superimposable to
that above described was also obtained in 73% yields when
the reaction was performed in CH3CN (4 mL) heating at 60 °C
for 7 h.
Methyl 5-acetamido-2,6-anhydro-4-(morpholin-4-yl)-7,8,9-tri-
O-acetyl-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonate (11).
The 2-hydroxy ester 9 (104 mg, 0.20 mmol) dissolved in
CH3CN (0.60 mL), was reacted with the TFAA (84 μL,
0.6 mmol) at 23 °C for 10 min. Then, the solvent and the excess
TFAA were evaporated under a nitrogen ﬂow to afford a crude
residue that was recovered in CH3CN (0.60 mL) and treated with
TFA (46 μL, 0.6 mmol) at 135 °C for 5 min, in a sealed tube.
Then, the reaction mixture was cooled, diluted with methanol
(0.20 mL) and evaporated under reduced pressure. The obtained
crude product (88 mg) that was then puriﬁed by rapid chromato-
graphy, to afford the appropriate glycal 11, as a white solid,
(80 mg, 80%): m.p. 110–112 °C; [α]20D + 65.0 (c 1 in CHCl3);
(Found: C, 52.76; H, 6.15; N, 5.79; Calc. for: C22H32N2O11 C,
52.79; H, 6.44; N, 5.60%); 1H NMR (CDCl3) δ 6.10 (1H, d, J3,4
= 3.1 Hz, 3-H), 5.57 (1H, dd, J7,8 = J7,6 = 4.0 Hz, 7-H),
5.55–5.38 (1H, br s, N–H), 5.35 (1H, ddd, J8,9b = 7.2, J8,7 = 4.0,
J8,9a = 3.3 Hz, 8-H), 4.62 (1H, dd, J9a,9b = 12.3, J9a,8 = 3.3 Hz,
9a-H), 4.38–4.32 (1H, m, 5-H), 4.29 (1H, dd, J6,5 = 8.0, J6,7 =
4.0 Hz, 6-H), 4.17 (1H, dd, J9b,9a = 12.3, J9b,8 = 7.2 Hz, 9b-H),
3.80 (3H, s, COOCH3), 3.73–3.59 (4H, overlapping, N
(CH2CH2)2O), 3.32 (1H, br s, 4-H), 2.83–2.70 (2H, overlapping,
N(CH2CH2)2O), 2.67–2.55 (2H, overlapping, N(CH2CH2)2O),
2.11 (3H, s, CH3COO), 2.06 (3H, s, CH3COO), 2.04 (3H, s,
CH3COO), 1.96 (3H, s, CH3CONH);
13C NMR (CDCl3) δ
170.5, 170.2, 170.1, 170.0 (4C, 3XCH3COO and NHCOCH3),
161.8 (C-1), 144.6 (C-2), 108.7 (C-3), 77.2 (C-6), 71.0 (C-8),
68.2 (C-7), 67.1 (2C, N(CH2CH2)2O), 62.6 (C-4), 62.1 (C-9),
52.3 (COOCH3), 49.7 (2C, N(CH2CH2)2O), 43.8 (C-5), 23.2
(NHCOCH3), 20.8 (1C, CH3COO), 20.7 (2C, 2XCH3COO); MS
(ESI positive) m/z 523.1 [M + Na]+, 1022.5 [2M + Na]+.
Methyl 5-acetamido-2,6-anhydro-4-(piperidin-1-yl)-7,8,9-tri-
O-acetyl-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonate (12).
The 2-hydroxy ester 10 (103 mg, 0.20 mmol), dissolved in
CH3CN (0.60 mL), was reacted with the TFAA (84 μL,
0.6 mmol) at 23 °C for 10 min. Then, the solvent and the TFAA
excess were evaporated under a nitrogen ﬂow to afford a crude
residue which was recovered in CH3CN (0.60 mL) and treated
with TFA (46 μL, 0.6 mmol) at 135 °C for 5 min, in a sealed
tube. Then, the reaction mixture was cooled, diluted with metha-
nol (0.20 mL) and evaporated under reduced pressure to afford a
crude product (90 mg) that was puriﬁed, by rapid chromato-
graphy, to afford the glycal 12 (81 mg, 78%), as a white solid:
m.p. 137–138 °C; [α]20D + 57.0 (c 1 in CHCl3); (Found: C,
55.40; H, 6.51; N, 5.59; Calc. for: C23H34N2O10 C, 55.41; H,
6.87; N, 5.62%); 1H NMR (CDCl3) δ 6.06 (1H, d, J3,4 = 3.0 Hz,
3-H), 5.61 (1H, d, JNH,5 = 9.4 Hz, N–H), 5.50 (1H, dd, J7,8 =
J7,6 = 3.7 Hz, 7-H), 5.30 (1H, ddd, J8,9b = 7.4, J8,7 = 3.7, J8,9a =
3.3 Hz, 8-H), 4.64 (1H, dd, J9a,9b = 12.3, J9a,8 = 3.3 Hz, 9a-H),
4.31–4.25 (1H, m, 5-H), 4.20 (1H, dd, J6,5 = 8.6, J6,7 = 3.7 Hz,
6-H), 4.14 (1H, dd, J9b,9a = 12.3, J9b,8 = 7.4 Hz, 9b-H), 3.75
(3H, s, COOCH3), 3.23 (1H, dd, J4,5 = 8.1, J4,3 = 3.0 Hz, 4-H),
2.65–2.57 (2H, overlapping, N(CH2CH2)2CH2), 2.47–2.40 (2H,
overlapping, N(CH2CH2)2CH2), 2.09 (3H, s, CH3COO),
2.03–2.00 (6H, overlapping, 2XCH3COO), 1.89 (3H, s,
CH3CONH), 1.54–1.32 (6H, overlapping, N(CH2CH2)2CH2);
13C NMR (CDCl3) δ 170.5, 170.2, 170.1, 170.0 (4C,
3XCH3COO and NHCOCH3), 162.0 (C-1), 144.2 (C-2), 110.7
(C-3), 77.4 (C-6), 71.3 (C-8), 68.2 (C-7), 63.1 (C-4), 62.1 (C-9),
52.2 (COOCH3), 50.5 (2C, N(CH2CH2)2CH2), 43.9 (C-5), 26.4
(2C, N(CH2CH2)2CH2), 24.4 (1C, N(CH2CH2)2CH2), 23.3
(NHCOCH3), 20.8 (2C, 2XCH3COO), 20.7 (1C, CH3COO); MS
(ESI positive) m/z 499.1 [M + H]+, 521.1 [M + Na]+, 1018.7
[2M + Na]+.
5-Acetamido-2,6-anhydro-4-(morpholin-4-yl)-3,4,5-trideoxy-D-
glycero-D-galacto-non-2-enoic acid (6d). The protected glycal 11
(50 mg, 0.10 mmol), dissolved in aqueous methanol (1.0 mL,
1 : 2 v/v) saturated with K2CO4, was stirred for 12 h at 23 °C.
Then the solution was treated with a acidic resin [DOWEX
50WX8 (H+)] and stirred for 15 min. The solution was ﬁltered
and the solvent was removed under reduced pressure to afford
the free glycal 6d (31 mg, 85%), as a white solid: m.
p. 182–184 °C; [α]20D + 28.6 (c 1 in CH3OH): (Found: C, 49.85;
H, 6.76; N, 7.71; Calc. for: C15H24N2O8, C, 49.99; H, 6.71; N,
7.77%); 1H NMR (D2O) δ 5.77 (1H, d, J3,4 = 2.8 Hz, 3-H), 4.36
(1H, t app., J5,4 = J5,6 = 9.4 Hz, 5-H), 4.17 (1H, d app, J6,5 = 9.4
Hz, 6-H), 3.9 (1H, ddd, J8,7 = 9.2, J8,9b = 6.2, J8,9a = 2.7 Hz, 8-
H), 3.80 (1H, dd, J9a,9b = 11.9, J9a,8 = 2.7 Hz, 9a-H), 3.79–3.80
(5H, overlapping, N(CH2CH2)2O and 4-H), 3.64 (1H, dd, J9b,9a
= 11.9, J9b,8 = 6.2 Hz, 9b-H), 3.60 (1H, dd, J7,8 = 9.2, J7,6 =
1.0Hz, 7-H), 2.81–2.74 (2H, overlapping, N(CH2CH2)2O),
2.70–2.64 (2H, overlapping, N(CH2CH2)2O), 2.04 (CH3CONH);
13C NMR (D2O) δ 174.4 (NHCOCH3), 168.9 (C-1), 151.2
(C-2), 101.2 (C-3), 75.8 (C-6), 69.9 (C-8), 68.5 (C-7), 66.3 (2C,
N(CH2CH2)2O), 63.1 (C-9), 62.7 (C-4), 48.6 (2C, N
(CH2CH2)2O), 42.8 (C-5), 22.3 (NHCOCH3); MS (ESI negative)
m/z 359.3 [M − H]−.
5-Acetamido-2,6-anhydro-4-(piperidin-1-yl)-3,4,5-trideoxy-D-
glycero-D-galacto-non-2-enoic acid (7d). The protected glycal 12
(50 mg, 0.10 mmol), dissolved in aqueous methanol (1.0 mL,
1 : 2 v/v) saturated with K2CO4, was stirred for 12 h at 23 °C.
Then the solution was treated with a acidic resin [DOWEX
50WX8 (H+)] and stirred for 15 min. The solution was ﬁltered
and the solvent was removed under reduced pressure to afford
the free glycal 7d (32 mg, 91%) as a white solid: m.
p. 166–168 °C; [α]20D + 24.3 (c 1 in CH3OH); (Found: Calc. for:
C, 53.63; H, 7.28; N, 7.80; C16H26N2O7 C, 53.62; H, 7.31; N,
7.82%); 1H NMR (D2O) δ 5.67 (1H, br s, 3-H), 4.51 (1H, t app.,
J5,4 = J5,6 = 10.2 Hz, 5-H), 4.23 (1H, d, J6,5 = 10.2 Hz, 6-H),
3.89–3.82 (1H, m, 8-H), 3.78 (1H, dd, J9a,9b = 12.0, J9a,8 = 1.8
Hz, 9a-H), 3.61–3.45 (3H, overlapping, 4-H, 9b-H and 7-H),
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3.43–3.20 (2H, overlapping, N(CH2CH2)2CH2), 3.10–2.74 (2H,
overlapping, N(CH2CH2)2CH2), 1.85 (3H, s, CH3CONH),
1.84–1.27 (6H, overlapping, N(CH2CH2)2CH2);
13C NMR
(D2O) δ 175.7 (NHCOCH3), 168.6 (C-1), 153.9 (C-2), 97.4
(C-3), 76.2 (C-6), 70.3 (C-8), 68.5 (C-7), 65.7 (C-9), 63.7 (C-4),
50.5 (2C, N(CH2CH2)2CH2), 43.0 (C-5), 23.9 (2C, N
(CH2CH2)2CH2), 22.8 (1C, N(CH2CH2)2CH2), 21.9
(CH3CONH); MS (ESI negative) m/z 357.1 [M − H]−.
Amination at the C-4 α-position of the N-perﬂuoroacylated
neuraminic acid methyl esters 15a–c. General procedure. The
appropriate N-perﬂuoracylated derivative20 (0.40 mmol), dis-
solved in CH3CN (4 mL) was reacted with the appropriate cyclic
amine (4.0 mmol) under stirring at 60 °C, for the reported time.
Then, the solvent was evaporated under reduced pressure, and
the residue was puriﬁed by rapid chromatography.
Methyl 5-(2,2,2-triﬂuoroacetamido)-4-(morpholin-4-yl)-7,8,9-
tri-O-acetyl-3,4,5-trideoxy-D-glycero-β-D-galacto-non-2-ulopyra-
nosidonate (16a). Starting with the amido ester 15a20 (235 mg,
0.40 mmol) and morpholine (0.35 mL, 4.0 mmol) the amino
derivative 16a was obtained, after 5 h, as a white solid (181 mg,
79%): m.p. 149–151 °C; [α]20D + 23.6 (c 1 in CHCl3); (Found: C,
46.26; H, 5.48; N, 4.96; Calc. for: C22H31F3N2O12 C, 46.16; H,
5.46; N, 4.89%); 1H NMR (CDCl3) δ 6.78 (1H, d, JNH,5 = 10.2
Hz, N–H), 5.34 (1H, dd, J7,8 = 4.7, J7,6 = 2.4 Hz, 7-H), 5.28
(1H, ddd, J8,9b = 7.3, J8,7 = 4.7, J8,9a = 2.4 Hz, 8-H), 4.74 (1H,
br s, OH), 4.55 (1H, dd, J9a,9b = 12.4, J9a,8 = 2.4 Hz, 9a-H), 4.30
(1H, dd, J6,5 = 10.3, J6,7 = 2.4 Hz, 6-H), 4.06–3.98 (2H, overlap-
ping, 5-H and 9b-H), 3.87 (3H, s, COOCH3), 3.65–3.50 (4H,
overlapping, N(CH2CH2)2O), 3.00–2.96 (1H, m, 4-H),
2.71–2.65 (2H, overlapping, N(CH2CH2)2O), 2.33–2.27 (2H,
overlapping, N(CH2CH2)2O), 2.17 (3H, s, CH3COO), 2.09–1.98
(8H, overlapping, 2XCH3COO, 3a-H and 3b-H);
13C NMR
(CDCl3) δ 171.2, 170.8, 169.8 (3C, 3XCH3COO), 169.4 (C-1),
157.8 (q, JC,F = 37 Hz, COCF3), 122.0–110.0 (1C, CF3), 95.1
(C-2), 71.4 (C-6 and C-8), 68.7 (C-7), 67.1 (2C, N
(CH2CH2)2O), 62.6 (C-9), 60.9 (C-4), 53.4 (COOCH3), 48.7
(2C, N(CH2CH2)2O), 46.8 (C-5), 29.4 (C-3), 20.8, 20.7, 20.5
(3C, 3XCH3COO); MS (ESI positive) m/z 573.2 [M + H]
+,
595.1 [M + Na]+, 1166 [2M + Na]+.
Methyl 5-(2,2,2-triﬂuoroacetamido)-4-(piperidin-1-yl)-7,8,9-
tri-O-acetyl-3,4,5-trideoxy-D-glycero-β-D-galacto-non-2-ulopyra-
nosidonate (17a). Starting with the amido ester 15a20 (235 mg,
0.40 mmol) and piperidine (0.40 mL, 4.0 mmol) the amino
derivative 17a was obtained, after 7 h, as a white solid (171 mg,
75%): m.p. 160–162 °C; [α]20D + 36.3 (c 1 in CHCl3); (Found: C,
48.37; H, 5.89; N, 4.79; Calc. for: C23H33F3N2O11 C, 48.42; H,
5.83; N, 4.91%); 1H NMR (CDCl3) δ 6.65 (1H, br s, N–H), 5.33
(1H, dd, J7,8 = 4.6, J7,6 = 2.1 Hz, 7-H), 5.32–5.28 (1H, m, 8-H),
4.66 (1H, br s, OH), 4.55 (1H, dd, J9a,9b = 12.3, J9,8 = 2.2 Hz,
9a-H), 4.27 (1H, dd, J6,5 = 10.2, J6,7 = 2.1 Hz, 6-H), 4.09–3.98
(2H, overlapping, 5-H and 9b-H), 3.86 (3H, s, COOCH3),
2.96–2.92 (1H, m, 4-H), 2.63–2.57 (2H, overlapping, N
(CH2CH2)2CH2), 2.26–2.19 (2H, overlapping, N(CH2CH2)2-
CH2), 2.14 (3H, s, CH3COO), 2.09 (3H, s, CH3COO),
2.06–1.95 (5H, overlapping, CH3COO, 3a-H and 3b-H),
1.55–1.32 (6H, overlapping, N(CH2CH2)2CH2);
13C NMR
(CDCl3) δ 171.3, 170.9, 170.0 (3C, 3XCH3COO), 169.8 (C-1),
157.8 (q, JC,F = 37 Hz, COCF3), 120.0–110.0 (1C, CF3), 95.4
(C-2), 72.0 (C-6), 71.7 (C-8), 69.0 (C-7), 62.7 (C-9), 61.4 (C-4),
53.4 (COOCH3), 49.8 (2C, N(CH2CH2)2CH2), 47.3 (C-5), 29.6
(C-3), 26.5 (2C, N(CH2CH2)2CH2), 24.7 (1C, N
(CH2CH2)2CH2), 20.9, 20.8, 20.7 (3C, 3XCH3COO); MS
(ESI positive) m/z 571.2 [M + H]+, 593.1 [M + Na]+, 1162.6
[2M + Na]+.
Methyl 5-(2,2,3,3,3-pentaﬂuoropropionamido)-4-(morpholin-
4-yl)-7,8,9-tri-O-acetyl-3,4,5-trideoxy-D-glycero-β-D-galacto-non-
2-ulopyranosidonate (16b). Starting with the amido ester 15b20
(255 mg, 0.40 mmol) and morpholine (0.35 mL, 4.0 mmol) the
amino derivative 16b was obtained, after 5 h, as a white solid
(204 mg, 82%): m.p. 154–156 °C; [α]20D + 23.6 (c 1 in CHCl3);
(Found: C, 44.58; H, 4.82; N, 4.38; Calc. for: C23H31F5N2O12
C, 44.38; H, 5.02; N, 4.50%); 1H NMR (CDCl3) δ 6.63 (1H, d,
JNH,5 = 10.0 Hz, N–H), 5.33 (1H, dd, J7,8 = 5.5, J7,6 = 2.2 Hz,
7-H), 5.25 (1H, ddd, J8,9b = 7.6, J8,7 = 5.5, J8,9a = 2.3 Hz, 8-H),
4.67 (1H, br s, OH), 4.50 (1H, dd, J9a,9b = 12.3, J9a,8 = 2.3 Hz,
9a-H), 4.27 (1H, dd, J6,5 = 10.3, J6,7 = 2.2 Hz, 6-H), 4.06–3.97
(2H, overlapping, 5-H and 9b-H), 3.87 (3H, s, COOCH3),
3.64–3.52 (4H, overlapping, N(CH2CH2)2O), 3.01 (1H, ddd,
J4,3a = J4,5 = 11.2, J4,3b = 4.7 Hz, 4-H), 2.71–2.64 (2H, overlap-
ping, N(CH2CH2)2O), 2.36–2.30 (2H, overlapping, N
(CH2CH2)2O), 2.12 (3H, s, CH3COO), 2.09–1.99 (8H, overlap-
ping, 2XCH3COO, 3a-H and 3b-H);
13C NMR (CDCl3) δ 171.4,
171.2, 170.0 (3C, 3XCH3COO), 169.3 (C-1), 158.3 (t, JC,F = 26
Hz; COCF2CF3), 120.0–108.0 (2C, CF2CF3), 95.4 (C-2), 71.6
(2C, C-6 and C-8), 69.1 (C-7), 67.2 (2C, N(CH2CH2)2O), 62.8
(C-9), 60.9 (C-4), 53.7 (COOCH3), 49.0 (2C, N(CH2CH2)2O),
47.4 (C-5), 29.4 (C-3), 20.9, 20.8, 20.7 (3C, 3XCH3COO); MS
(ESI positive) m/z 623.6 [M + H]+, 646.7 [M + Na]+, 1268.1
[2M + Na]+.
Methyl 5-(2,2,3,3,3-pentaﬂuoropropionamido)-4-(piperidin-1-
yl)-7,8,9-tri-O-acetyl-3,4,5-trideoxy-D-glycero-β-D-galacto-non-2-
ulopyranosidonate (17b). Starting with the amido ester 15b20
(255 mg, 0.40 mmol) and piperidine (0.40 mL, 4.0 mmol) the
amino derivative 17b was obtained, after 7 h, as a white solid
(176 mg, 71%): m.p. 151–153 °C; [α]20D + 23.0 (c 1 in CHCl3);
(Found: C, 46.51; H, 5.26; N, 4.42; Calc. for: C24H33F5N2O11
C, 46.45; H, 5.36; N, 4.51%); 1H NMR (CDCl3) δ 6.92 (1H, d,
JNH,5 = 8.2 Hz, N–H), 5.31 (1H, dd, J7,8 = 4.3, J7,6 = 2.1 Hz, 7-
H), 5.29–5.26 (1H, m, 8-H), 4.76 (1H, br s, OH), 4.58 (1H, dd,
J9a,9b = 12.3, J9a,8 = 2.2 Hz, 9a-H), 4.30 (1H, dd, J6,5 = 10.3,
J6,7 = 2.1 Hz, 6-H), 4.14–4.05 (1H, m, 5-H), 4.00 (1H, dd, J9b,9a
= 12.3, J9b,8 = 7.7 Hz, 9b-H), 3.85 (3H, s, COOCH3), 2.94 (1H,
ddd, J4,3a = J4,5 = 11.0 Hz, J4,3b = 5.0 Hz, 4-H), 2.63–2.53 (2H,
overlapping, N(CH2CH2)2CH2), 2.23–2.16 (2H, overlapping, N
(CH2CH2)2CH2), 2.13 (3H, s, CH3COO), 2.07 (3H, s,
CH3COO), 2.03–1.86 (5H, overlapping, CH3COO, 3a-H and 3b-
H), 1.52–1.31 (6H, overlapping, N(CH2CH2)2CH2);
13C NMR
(CDCl3) δ 171.7, 170.9, 169.9 (3C, 3XCH3COO), 169.8 (C-1),
158.3 (t, JC,F = 27 Hz; COCF2CF3), 120.0–110.0 (2C, CF2CF3),
95.4 (C-2), 72.3 (C-6), 72.0 (C-8), 69.2 (C-7), 62.7 (C-9), 61.1
(C-4), 53.3 (COOCH3), 49.8 (2C, N(CH2CH2)2CH2), 47.0
(C-5), 29.3 (C-3), 26.2 (2C, N(CH2CH2)2CH2), 24.7 (1C, N
(CH2CH2)2CH2), 20.8, 20.7, 20.6 (3C, 3XCH3COO); MS (ESI
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positive) m/z 621.2 [M + H]+, 643.7 [M + Na]+, 1264.1
[2M + Na]+.
Methyl 5-(2,2,3,3,4,4,4-heptaﬂuorobutanamido)-4-(morpholin-
4-yl)-7,8,9-tri-O-acetyl-3,4,5-trideoxy-β-D-glycero-D-galacto-non-
2-ulopyranosidonate (16c). Starting with the amido ester 15c20
(275 mg, 0.40 mmol) and morpholine (0.35 mL, 4.0 mmol) the
amino derivative 16c was obtained, after 5 h, as a white solid
(215 mg, 80%): m.p. 148–150 °C; [α]20D + 36.5 (c 1 in CHCl3);
(Found: C, 42.38; H, 4.76; N, 4.28; Calc. for: C24H31F7N2O12
C, 42.86; H, 4.65; N, 4.17%); 1H NMR (CDCl3) δ 6.87 (1H, d,
JNH,5 = 9.8 Hz, N–H), 5.31 (1H, dd, J7,8 = 4.8, J7,6 = 2.3 Hz, 7-
H), 5.26 (1H, ddd, J8,9b = 7.3, J8,7 = 4.8, J8,9a = 2.3 Hz, 8-H),
4.80 (1H, br s, OH), 4.57 (1H, dd, J9a,9b = 12.4, J9a,8 = 2.3 Hz,
9a-H), 4.31 (1H, dd, J6,5 = 10.3, J6,7 = 2.3 Hz, 6-H), 4.06–4.02
(1H, m, 5-H), 3.99 (1H, dd, J9b,9a = 12.4, J9b,8 = 7.3 Hz, 9b-H),
3.87 (3H, s, COOCH3), 3.63–3.51 (4H, overlapping, N
(CH2CH2)2O), 3.00 (1H, ddd, J4,3a = J4–5 = 11.0, J4,3b = 5.3 Hz,
4-H), 2.71–2.65 (2H, overlapping, N(CH2CH2)2O), 2.32–2.27
(2H, overlapping, N(CH2CH2)2O), 2.13 (3H, s, CH3COO),
2.09–1.99 (8H, overlapping, 2XCH3COO, 3a-H and 3b-H);
13C
NMR (CDCl3) δ 171.2, 171.0, 169.8 (3C, 3XCH3COO), 169.7
(C-1), 158.2 (t, JC,F = 26 Hz; COCF2CF2CF3), 121.0–108.0 (3C,
CF2CF2CF3), 95.3 (C-2), 71.4 (2C, C-6 and C-8), 69.0 (C-7),
67.0 (2C, N(CH2CH2)2O), 62.6 (C-9), 60.7 (C-4), 53.5
(COOCH3), 48.8 (2C, N(CH2CH2)2O), 47.2 (C-5), 29.2 (C-3),
20.7, 20.6, 20.5 (3C, 3XCH3COO); MS (ESI positive) m/z 673.1
[M + H]+, 695.0 [M + Na]+.
Methyl 5-(2,2,3,3,4,4,4-heptaﬂuorobutanamido)-4-(piperidin-
1-yl)-7,8,9-tri-O-acetyl-3,4,5-trideoxy-β-D-glycero-D-galacto-non-
2-ulopyranosidonate. (17c). Starting with the amido ester 15c20
(255 mg, 0.40 mmol) and piperidine (0.40 mL, 4.0 mmol) the
amino ester 17c was obtained, after 7 h, as a white solid
(190 mg, 71%): m.p. 140–142 °C; [α]20D + 31.2 (c 1 in CHCl3);
(Found: C, 44.34; H, 4.81; N, 4.24; Calc. for: C25H33F7N2O11
C, 44.78; H, 4.96; N 4.18%); 1H NMR (CDCl3) δ 7.12 (1H, br
s, N–H), 5.32–5.26 (2H, overlapping, 7-H and 8-H), 4.95 (1H,
br s, OH), 4.63 (1H, dd, J9a,9b = 12.4, J9,8 = 2.4 Hz, 9a-H), 4.32
(1H, dd, J6,5 = 10.3, J6,7 = 2.2 Hz, 6-H), 4.18–4.04 (1H, m,
5-H), 3.99 (1H, dd, J9b,9a = 12.4, J9b,8 = 7.4 Hz, 9b-H), 3.84
(3H, s, COOCH3), 2.97–2.90 (1H, m, 4-H), 2.62–2.54 (2H,
overlapping, N(CH2CH2)2CH2), 2.22–2.15 (2H, overlapping, N
(CH2CH2)2CH2), 2.13 (3H, s, CH3COO), 2.06 (3H, s,
CH3COO), 2.03–1.96 (5H, overlapping, CH3COO, 3a-H and 3b-
H), 1.50–1.30 (6H, overlapping, N(CH2CH2)2CH2);
13C NMR
(CDCl3) δ 171.7, 170.0, 169.9 (3C, 3XCH3COO), 169.8 (C-1),
158.3 (t, JC,F = 27 Hz; COCF2CF2CF3), 120.0–105.0 (3C,
CF2CF2CF3), 95.4 (C-2), 72.3 (C-6), 72.0 (C-8), 69.3 (C-7),
62.6 (C-9), 60.9 (C-4), 53.3 (COOCH3), 49.7 (2C, N
(CH2CH2)2CH2), 47.2 (C-5), 29.3 (C-3), 26.2 (2C, N(CH2CH2)2-
CH2), 24.7 (1C, N(CH2CH2)2CH2), 20.7 (CH3COO), 20.6 (2C,
2XCH3COO); MS (ESI positive) m/z 671.2 [M + H]
+, 693.1
[M + Na]+, 1362.6 [2M + Na]+.
Dehydration of 4α-aminated 2-hydroxy peracetylated sialic
acid esters 16a–c and 17a–c. General procedure. The 2-hydroxy
peracetylated sialic acid amino ester (0.20 mmol), dissolved in
CH3CN (0.60 mL), was reacted with the TFAA (84 μL,
0.6 mmol) at 23 °C for 10 min. Then, the solvent and the excess
TFAAwere evaporated under a nitrogen ﬂow and the crude was
dissolved in CH3CN (0.60 mL) and treated with TFA (46 μL,
0.6 mmol) at 135 °C for 5 min, in a sealed tube. The reaction
mixture was cooled, diluted with methanol (0.20 mL) and evap-
orated under reduced pressure. The obtained crude residue was
puriﬁed by rapid chromatography, to afford the appropriate
glycal.
Methyl 2,6-anhydro-5-(2,2,2-triﬂuoroacetamido)-4-(morpho-
lin-4-yl)-7,8,9-tri-O-acetyl-3,4,5-trideoxy-D-glycero-D-galacto-non-
2-enonate. (13a). Starting from the 2-hydroxy compound 16a
(114 mg, 0.20 mmol) the glycal 13a (88 mg, 79%) was obtained,
as a white solid: m.p. 138–140 °C; [α]20D + 84.9 (c 1 in CHCl3);
(Found: C, 47.99; H, 5.46; N, 5.11; Calc. for: C22H29F3N2O11
C, 47.66; H, 5.27; N, 5.05%); 1H NMR (CDCl3) δ 7.09 (1H, d,
JNH,5 = 9.6 Hz, N–H), 6.10 (1H, d, J3,4 = 2.6 Hz, 3-H), 5.50
(1H, dd, J7,8 = 4.3, J7,6 = 2.7 Hz, 7-H), 5.30–5.25 (1H, m, 8-H),
4.77 (1H, dd, J9a,9b = 12.4, J9a,8 = 3.0 Hz, 9a-H), 4.34 (1H, dd,
J6,5 = 9.0, J6,7 = 2.7 Hz, 6-H), 4.30–4.24 (1H, m, 5-H), 4.11
(1H, dd, J9b,9a = 12.4, J9b,8 = 7.6 Hz, 9b-H), 3.78 (3H, s,
COOCH3), 3.65–3.53 (4H, overlapping, N(CH2CH2)2O), 3.36
(1H, dd, J4,5 = 9.1, J4,3 = 2.6 Hz, 4-H), 2.74–2.67 (2H, over-
lapping, N(CH2CH2)2O), 2.45–2.43 (2H, overlapping,
N(CH2CH2)2O), 2.09 (3H, s, CH3COO), 2.02 (6H, overlapping,
2XCH3COO);
13C NMR (CDCl3) δ 171.0, 170.5, 169.9 (3C,
3XCH3COO), 161.5 (C-1), 157.6 (q, JC,F = 37 Hz, COCF3),
145.0 (C-2), 122.0–110.0 (1C, CF3), 108.4 (C-3), 76.6 (C-6),
71.3 (C-8), 68.1 (C-7), 67.1 (2C, N(CH2CH2)2O), 62.6 (C-4),
62.0 (C-9), 52.4 (COOCH3), 49.3 (2C, N(CH2CH2)2O), 44.2
(C-5), 22.8 (NHCOCH3), 20.7, 20.6, 20.5 (3C, 3XCH3COO);
MS (ESI positive) m/z 555.8 [M + H]+, 577.1 [M + Na]+, 1131.5
[2M + Na]+.
Methyl 2,6-anhydro-5-(2,2,2-triﬂuoroacetamido)-4-(piperidin-
1-yl)-7,8,9-tri-O-acetyl-3,4,5-trideoxy-D-glycero-D-galacto-non-2-
enonate (14a). Starting from the 2-hydroxy compound 17a
(114 mg, 0.20 mmol) the glycal 14a (84 mg, 77%) was obtained,
as a white solid: m.p. 123–125 °C; [α]20D + 89.5 (c 1 in CHCl3);
(Found: C, 50.26; H, 5.67; N, 4.98; Calc. for: C23H31F3N2O10
C, 50.00; H, 5.66; N, 5.07%); 1H NMR (CDCl3) δ 6.96 (1H, br
d, JNH,5 = 8.7 Hz, N–H), 6.10 (1H, d, J3,4 = 2.6 Hz, 3-H), 5.48
(1H, dd, J7,8 = 4.1, J7,6 = 2.6 Hz, 7-H), 5.28 (1H, ddd, J8,9b =
7.3, J8,7 = 4.1, J8,9a = 3.1 Hz, 8-H), 4.74 (1H, dd, J9a,9b = 12.3,
J9a,8 = 3.1 Hz, 9a-H), 4.34–4.24 (2H, overlapping, 6-H and 5-
H), 4.13 (1H, dd, J9b,9a = 12.3, J9b,8 = 7.3 Hz, 9b-H), 3.78 (3H,
s, COOCH3), 3.36 (1H, dd, J4,5 = 8.6, J4,3 = 2.2 Hz, 4-H),
2.66–2.58 (2H, overlapping, N(CH2CH2)2CH2), 2.41–2.34 (2H,
overlapping, N(CH2CH2)2CH2), 2.10 (3H, s, CH3COO), 2.03
(6H, overlapping, 2XCH3COO), 1.54–1.34 (6H, overlapping, N
(CH2CH2)2CH2);
13C NMR (CDCl3) δ 170.9, 170.5, 170.0 (3C,
3XCH3COO), 161.7 (C-1), 157.7 (q, JC,F = 37 Hz, COCF3),
144.5 (C-2), 120.0–110.0 (1C, CF3), 110.1 (C-3), 76.7 (C-6),
71.4 (C-8), 68.1 (C-7), 63.1 (C-4), 62.1 (C-9), 52.3 (COOCH3),
50.3 (2C, N(CH2CH2)2CH2), 44.6 (C-5), 26.3 (2C, N
(CH2CH2)2CH2), 22.8 (1C, N(CH2CH2)2CH2), 20.7 (2C,
2XCH3COO), 20.5 (CH3COO); MS (ESI positive) m/z 553.3 [M
+ H]+, 575.1 [M + Na]+, 1129.4 [2M + Na]+.
Methyl 2,6-anhydro-5-(2,2,3,3,3-pentaﬂuoropropionamido)-4-
(morpholin-4-yl)-7,8,9-tri-O-acetyl-3,4,5-trideoxy-D-glycero-D-
galacto-non-2-enonate (13b). Starting from the 2-hydroxy
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compound 16b (124 mg, 0.20 mmol) the glycal 13b (97 mg,
80%) was obtained, as a white solid: m.p. 128–130 °C; [α]20D +
78.2 (c 1 in CHCl3); (Found: C, 45.98; H, 4.68; N, 4.69; Calc.
for: C23H29F5N2O11 C, 45.70; H, 4.84; N, 4.63%);
1H NMR
(CDCl3) δ 6.95 (1H, d, JNH,5 = 9.7 Hz, N–H), 6.13 (1H, d, J3,4 =
2.5 Hz, 3-H), 5.48 (1H, dd, J7,8 = 4.2, J7,6 = 2.7 Hz, 7-H), 5.29
(1H, ddd, J8,9b = 7.3, J8,7 = 4.2, J8,9a = 3.0 Hz, 8-H), 4.75 (1H,
dd, J9a,9b = 12.3, J9a,8 = 3.0 Hz, 9a-H), 4.37 (1H, dd, J6,5 = 9.6,
J6,7 = 2.7 Hz, 6-H), 4.32–4.25 (1H, m, 5-H), 4.14 (1H, dd, J9b,9a
= 12.3, J9b,8 = 7.3 Hz, 9b-H), 3.80 (3H, s, COOCH3), 3.67–3.54
(4H, overlapping, N(CH2CH2)2O), 3.37 (1H, dd, J4,5 = 9.3, J4,3
= 2.5 Hz, 4-H), 2.75–2.68 (2H, overlapping, N(CH2CH2)2O),
2.47–2.41 (2H, overlapping, N(CH2CH2)2O), 2.10 (3H, s,
CH3COO), 2.05 (3H, s, CH3COO), 2.04 (3H, s, CH3COO);
13C
NMR (CDCl3) δ 170.9, 170.5, 169.9 (3C, 3XCH3COO), 161.5
(C-1), 158.3 (t, JC–F = 26 Hz, COCF2CF3), 145.0 (C-2),
120.0–108.0 (2C, CF2CF3), 108.2 (C-3), 76.4 (C-6), 71.2 (C-8),
68.1 (C-7), 67.0 (2C, N(CH2CH2)2O), 62.8 (C-4), 62.0 (C-9),
52.5 (COOCH3), 49.2 (2C, N(CH2CH2)2O), 44.4 (C-5), 20.8,
20.6, 20.5 (3C, 3XCH3COO); MS (ESI positive) m/z 605.2
[M + H]+, 627.1 [M + Na]+.
Methyl 2,6-anhydro-5-(2,2,3,3,3-pentaﬂuoropropionamido)-4-
(piperidin-1-yl)-7,8,9-tri-O-acetyl-3,4,5-trideoxy-D-glycero-D-
galacto-non-2-enonate (14b). Starting from the 2-hydroxy com-
pound 17b (124 mg, 0.20 mmol) the glycal 14b (98 mg, 81%)
was obtained, as a white solid: m.p. 140–143 °C; [α]20D + 59.7
(c 1 in CHCl3); (Found: C, 47.92; H, 5.12; N, 4.56; Calc. for:
C24H31F5N2O10 C, 47.84; H, 5.19; N, 4.65%);
1H NMR
(CDCl3) δ 6.88 (1H, br s, N–H), 6.12 (1H, d, J3,4 = 2.5 Hz, 3-
H), 5.46 (1H, dd, J7,8 = 4.4, J7,6 = 2.5 Hz, 7-H), 5.29 (1H, ddd,
J8,9b = 7.2, J8,7 = 4.4, J8,9a = 2.8 Hz, 8-H), 4.73 (1H, dd, J9a,9b =
12.3, J9a,8 = 2.8 Hz, 9a-H), 4.35 (1H, dd, J6,5 = 9.6, J6,7 = 2.5
Hz, 6-H), 4.32–4.26 (1H, m, 5-H), 4.14 (1H, dd, J9b,9a = 12.3,
J9b,8 = 7.2 Hz, 9b-H), 3.79 (3H, s, COOCH3), 3.37 (1H, dd, J4,5
= 8.6, J4,3 = 2.5 Hz, 4-H), 2.67–2.59 (2H, overlapping,
N(CH2CH2)2CH2), 2.40–2.32 (2H, overlapping, N(CH2CH2)2-
CH2), 2.11 (3H, s, CH3COO), 2.04 (3H, s, CH3COO), 2.03 (3H,
s, CH3COO), 1.55–1.35 (6H, overlapping, N(CH2CH2)2CH2);
13C NMR (CDCl3) δ 170.8, 170.4, 170.0 (3C, 3XCH3COO),
161.7 (C-1), 158.2, (t, JC,F = 26 Hz, COCF2CF3), 144.6 (C-2),
120.0–110.0 (2C, CF2CF3), 109.7 (C-3), 76.6 (C-6), 71.2 (C-8),
68.1 (C-7), 63.2 (C-4), 62.0 (C-9), 52.4 (COOCH3), 50.3 (2C, N
(CH2CH2)2CH2), 44.9 (C-5), 26.2 (2C, N(CH2CH2)2CH2), 24.4
(1C, N(CH2CH2)2CH2), 20.8, 20.6, 20.5 (3C, 3XCH3COO); MS
(ESI positive) m/z 603.2 [M + H]+, 625.3 [M + Na]+.
Methyl 2,6-anhydro-5-(2,2,3,3,4,4,4-heptaﬂuorobutanamido)-
4-(morpholin-4-yl)-7,8,9-tri-O-acetyl-3,4,5-trideoxy-D-glycero-
D-galacto-non-2-enonate (13c). Starting from the 2-hydroxy
compound 16c (135 mg, 0.20 mmol) the glycal 13c (105 mg,
81%) was obtained, as a white solid: m.p. 127–129 °C; [α]20D +
77.7 (c 1 in CHCl3); (Found: C, 44.15; H, 4.53; N, 4.20; Calc.
for: C24H29F7N2O11 C, 44.04; H, 4.47; N, 4.28%);
1H NMR
(CDCl3) δ 6.97 (1H, d, JNH,5 = 9.5 Hz, N–H), 6.13 (1H, d, J3,4 =
2.4 Hz, 3-H), 5.48 (1H, dd, J7,8 = 4.3, J7,6 = 2.8 Hz, 7-H),
5.32–5.27 (1H, m, 8-H), 4.73 (1H, dd, J9a,9b = 12.3, J9a,8 = 3.0
Hz, 9a-H), 4.39 (1H, dd, J6,5 = 9.5, J6,7 = 2.8 Hz, 6-H),
4.31–4.22 (1H, m, 5-H), 4.15 (1H, dd, J9b,9a = 12.3, J9b,8 = 7.2
Hz, 9b-H), 3.80 (3H, s, COOCH3), 3.67–3.52 (4H, overlapping,
N(CH2CH2)2O), 3.40 (1H, dd, J4,5 = 9.2, J4,3 = 2.4 Hz, 4-H),
2.75–2.67 (2H, overlapping, N(CH2CH2)2O), 2.48–2.40 (2H,
overlapping, N(CH2CH2)2O), 2.11 (3H, s, CH3COO), 2.05 (3H,
s, CH3COO), 2.03 (3H, s, CH3COO);
13C NMR (CDCl3) δ
170.8, 170.4, 170.0 (3C, 3XCH3COO), 161.5 (C-1), 158.1 (t,
JC,F = 26 Hz, COCF2CF2CF3), 145.0 (C-2), 126.0–108.0 (3C,
CF2CF2CF3), 108.2 (C-3), 76.3 (C-6), 71.1 (C-8), 68.0 (C-7),
66.9 (2C, N(CH2CH2)2O), 62.6 (C-4), 61.6 (C-9), 52.5
(COOCH3), 49.2 (2C, N(CH2CH2)2O), 44.6 (C-5), 20.8, 20.6,
20.5 (3C, 3XCH3COO); MS (ESI positive) m/z 654.9 [M + H]
+,
677.1 [M + Na]+, 1330.5 [2M + Na]+.
Methyl 2,6-anhydro-5-(2,2,3,3,4,4,4-heptaﬂuorobutanamido)-
4-(piperidin-1-yl)-7,8,9-tri-O-acetyl-3,4,5-trideoxy-D-glycero-D-
galacto-non-2-enonate (14c). Starting from the 2-hydroxy
compound 17c (134 mg, 0.20 mmol) the glycal 14c (103 mg,
79%) was obtained, as a white solid: m.p. 137–139 °C; [α]20D +
93.0 (c 1 in CHCl3); (Found: C, 45.94; H, 4.68; N, 4.33; Calc.
for: C25H31F7N2O10 C, 46.02; H, 4.79; N, 4.29%);
1H NMR
(CDCl3) δ 6.90 (1H, br s, N–H), 6.12 (1H, d, J3,4 = 2.6 Hz, 3-
H), 5.45 (1H, dd, J7,8 = 4.3, J7,6 = 2.6 Hz, 7-H), 5.30–5.26 (1H,
m, 8-H), 4.73 (1H, dd, J9a,9b = 12.3, J9a,8 = 2.9 Hz, 9a-H), 4.37
(1H, dd, J6,5 = 9.0, J6,7 = 2.6 Hz, 6-H), 4.28–4.21 (1H, m, 5-H),
4.14 (1H, dd, J9b,9a = 12.3, J9b,8 = 7.2 Hz, 9b-H), 3.77 (3H, s,
COOCH3), 3.39 (1H, dd, J4,5 = 9.1, J4,3 = 2.6 Hz, 4-H),
2.68–2.57 (2H, overlapping, N(CH2CH2)2CH2), 2.39–2.31 (2H,
overlapping, N(CH2CH2)2CH2), 2.10 (3H, s, CH3COO), 2.03
(3H, s, CH3COO), 2.02 (3H, s, CH3COO), 1.53–1.34 (6H, over-
lapping, N(CH2CH2)2CH2);
13C NMR (CDCl3) δ 170.6, 170.2,
169.8 (3C, 3XCH3COO), 161.5 (C-1), 158.0, (t, JC,F = 26 Hz,
COCF2CF2CF3), 144.4 (C-2), 120.0–110.0 (2C, CF2CF2CF3),
109.5 (C-3), 76.4 (C-6), 71.1 (C-8), 67.9 (C-7), 63.0 (C-4), 61.8
(C-9), 52.1 (COOCH3), 50.2 (2C, N(CH2CH2)2CH2), 44.7
(C-5), 26.0 (2C, N(CH2CH2)2CH2), 24.2 (1C, N
(CH2CH2)2CH2), 20.6, 20.4, 20.3 (3C, 3XCH3COO); MS (ESI
positive) m/z 653.1 [M + H]+, 675.2 [M + Na]+, 1326.6
[2M + Na]+.
Selective hydrolysis of 4α-aminated N-perﬂuoracyl glycals
13a–c and 14a–c. General procedure. The appropriate protected
glycal (0.1 mmol) dissolved in methanol–water (1.5 mL, 2 : 1
v/v) was treated with Et3N (0.90 mL) under stirring for 12 h at
23 °C. Then the solvent was removed under reduced pressure
and the residue was recovered with water and lyophilized many
times until complete elimination of Et3N.
2,6-Anhydro-5-(2,2,2-triﬂuoroacetamido)-4-(morpholin-4-yl)-
3,4,5-trideoxy-D-glycero-D-galacto-non-2-enoic acid (6a). Starting
from the protected glycal 13a (55 mg, 0.10 mmol) the free
glycal 6a (39 mg, 93%) was obtained, as a white solid: m.
p. 187–189 °C; [α]20D + 28.6 (c 1 in CH3OH); (Found: C, 43.54;
H, 5.06; N, 6.68; Calc. for: C15H21F3N2O8 C, 43.48; H, 5.11; N,
6.76%); 1H NMR (D2O) δ 5.84 (1H, d, J3,4 = 2.2 Hz, 3-H), 4.50
(1H, t app., J5,4 = J5,6 = 10.0 Hz, 5-H), 4.33 (1H, d, J6,5 = 10.0
Hz, 6-H), 3.96 (1H, ddd, J8,7 = 9.3, J8,9b = 6.6, J8,9a = 2.6 Hz,
8-H), 3.89 (1H, dd, J9a,9b = 12.0, J9a,8 = 2.6 Hz, 9a-H),
3.77–3.59 (6H, overlapping, N(CH2CH2)2, 4-H and 9b-H), 3.56
(1H, d app, J7,8 = 9.3 Hz, 7-H), 2.83–2.75 (2H, overlapping, N
(CH2CH2)2O), 2.63–2.56 (2H, overlapping, N(CH2CH2)2O);
13C
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NMR (D2O) δ 169.8 (C-1), 159.3 (q, JC,F = 37 Hz, COCF2),
150.5 (C-2), 121.0–110.0 (1C, CF3), 104.3 (C-3), 75.9 (C-6),
70.6 (C-8), 69.3 (C-7), 67.2 (2C, N(CH2CH2)2O), 63.8 (C-9),
62.1 (C-4), 49.0 (2C, N(CH2CH2)2O), 44.7 (C-5); MS (ESI
negative) m/z 413.3 [M − H]−.
2,6-anhydro-5-(2,2,2-triﬂuoroacetamido)-4-(piperidin-1-yl)-3,4,5-
trideoxy-D-glycero-D-galacto-non-2-enoic acid (7a). Starting from
compound 14a (55 mg, 0.10 mmol) the free glycal 7a was
obtained (35 mg, 85%), as slightly yellow solid: m.
p. 155–157 °C; [α]20D + 31.2 (c 1 in CH3OH); (Found: C, 46.56;
H, 5.58; N, 6.79; Calc. for: C16H23F3N2O7 C, 46.60; H, 5.62; N,
6.79%); 1H NMR (D2O) δ 5.99 (1H, d, J3,4 = 2.7 Hz, 3-H), 4.60
(1H, t app., J5,4 = J5,6 = 9.3 Hz, 5-H), 4.41 (1H, d app., J6,5 =
9.3 Hz, 6-H), 3.91 (1H, ddd, J8,7 = 9.0, J8,9b = 6.1, J8,9a = 2.2
Hz, 8-H), 3.87 (1H, dd, J9a,9b = 12.0, J9a,8 = 2.2 Hz, 9a-H), 3.78
(1H, br s, 4-H), 3.66 (1H, dd, J9b,9a = 12.0, J9b,8 = 6.1 Hz, 9b-
H), 3.62 (1H, d, J7,8 = 9.0 Hz, 7-H), 2.82–2.73 (2H, overlapping,
N(CH2CH2)2CH2), 2.69–2.59 (2H, overlapping, N(CH2-
CH2)2CH2), 1.64–1.45 (6H, overlapping, N(CH2CH2)2CH2);
13C
NMR (D2O) δ 169.3 (C-1), 160.2 (t, JC,F = 26 Hz, COCF2CF3),
152.2 (C-2), 119.5–107.4 (2C, CF2CF3), 107.3 (C-3), 76.0
(C-6), 70.5 (C-8), 69.0 (C-7), 63.7 (C-9), 59.7 (C-4), 50.6 (2C,
N(CH2CH2)2CH2), 44.0 (C-5), 24.7 (2C, N(CH2CH2)2CH2),
23.1 (1C, N(CH2CH2)2CH2); MS (ESI negative) m/z 411.3
[M − H]−.
2,6-anhydro-5-(2,2,3,3,3-pentaﬂuoropropionamido)-4-(morpholin-
4-yl)-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enoic acid (6b).
Starting from the protected glycal 13b (60 mg, 0.10 mmol) the
free glycal 6b (42 mg, 91%) was obtained, as a white solid: m.
p. 144–146 °C; [α]20D + 26.4 (c 1 in CH3OH); (Found: C, 41.25;
H, 4.50; N, 6.00; Calc. for: C16H21F5N2O8 C, 41.39; H, 4.56; N,
6.03%); 1H NMR (D2O) δ 5.84 (1H, d, J3,4 = 2.2 Hz, 3-H), 4.75
(1H, t app., J5,4 = J5,6 = 9.6 Hz, 5-H), 4.44 (1H, d, J6,5 = 9.6 Hz,
6-H), 4.40 (1H, dd, J4,5 = 9.6, J4,3 = 2.4 Hz, 4-H), 4.04–3.96
(2H, overlapping, N(CH2CH2)2O), 3.96–3.88 (3H, overlapping,
N(CH2CH2)2O and 8-H), 3.84 (1H, dd, J9a,9b = 11.9, J9a,8 = 2.5
Hz, 9a-H), 3.58 (1H, dd, J9b,9a = 11.9, J9b,8 = 6.3 Hz 9b-H),
3.56–3.48 (3H, overlapping, N(CH2CH2)2O and 7-H), 3.29–3.21
(2H, overlapping, N(CH2CH2)2O);
13C NMR (D2O) δ 167.5
(C-1), 160.0 (t, JC,F = 26 Hz, COCF2), 153.3 (C-2), 119.5–107.4
(2C, CF2CF3), 96.6 (C-3), 75.4 (C-6), 69.7 (C-8), 68.2 (C-7),
63.9 (3C, N(CH2CH2)2O and C-9), 63.0 (C-4), 48.7 (2C,
N(CH2CH2)2O), 43.2 (C-5); MS (ESI negative) m/z 463.2
[M − H]−.
2,6-anhydro-5-(2,2,3,3,3-pentaﬂuoropropionamido)-4-(piperidin-
1-yl)-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enoic acid (7b).
Starting from the protected glycal 14b (60 mg, 0.10 mmol) the
free glycal 7b (39 mg, 84%) was obtained, as slightly yellow
solid: m.p. 155–157 °C; [α]20D + 22.3 (c 1 in CH3OH); (Found:
C, 44.09; H, 4.96; N, 6.03; Calc. for: C17H23F5N2O7 C, 44.16;
H, 5.01; N, 6.06%); 1H NMR (D2O) δ 5.80 (1H, d, J3,4 = 2.5
Hz, 3-H), 4.73 (1H, t app., J5,4 = J5,6 = 10.0 Hz, 5-H), 4.40 (1H,
d app, J6,5 = 10.0 Hz, 6-H), 4.22 (1H, br s, 4-H), 3.96 (1H, ddd,
J8,7 = 9.3, J8–9b = 6.3, J8,9a = 2.4 Hz, 8-H), 3.89 (1H, dd, J9a,9b
= 11.9, J9a,8 = 2.4 Hz, 9a-H), 3.62 (1H, dd, J9b,9a = 11.9, J9b,8 =
6.3 Hz, 9b-H), 3.54 (1H, d app., J7,8 = 9.3 Hz, 7-H),
3.33–3.19 (2H, overlapping, N(CH2CH2)2CH2), 3.09–2.96 (2H,
overlapping, N(CH2CH2)2CH2), 1.81–1.55 (6H, overlapping,
N(CH2CH2)2CH2);
13C NMR (D2O) δ 168.3 (C-1), 159.8 (t, JC,F
= 26 Hz, COCF2CF3), 152.4 (C-2), 119.5–107.4 (2C, CF2CF3),
99.3 (C-3), 75.4 (C-6), 69.8 (C-8), 68.3 (C-7), 63.3 (C-9), 63.1
(C-4), 50.2 (2C, N(CH2CH2)2CH2), 43.3 (C-5), 23.7 (2C,
N(CH2CH2)2CH2), 22.0 (1C, N(CH2CH2)2CH2); MS (ESI nega-
tive) m/z 461.1 [M − H]−.
2,6-anhydro-5-(2,2,3,3,4,4,4-heptaﬂuorobutanamido)-4-(morpho-
lin-4-yl)-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enoic acid (6c).
Starting from the protected glycal 13c (65 mg, 0.10 mmol) the
free glycal 6c (48 mg, 94%) was obtained, as a white solid: m.
p. 148–151 °C; [α]20D + 25.7 (c 1 in CH3OH); (Found: C, 39.65;
H, 4.09; N, 5.50; Calc. for: C17H21F7N2O8 C, 39.70; H, 4.12; N,
5.45%); 1H NMR (D2O) δ 5.84 (1H, d, J3,4 = 2.4 Hz, 3-H), 4.52
(1H, t app., J5,4 = J5,6 = 9.9 Hz, 5-H), 4.34 (1H, d, J6,5 = 9.9 Hz,
6-H), 3.95 (1H, ddd, J8,7 = 9.4, J8,9b = 6.6, J8,9a = 2.5 Hz, 8-H),
3.89 (1H, dd, J9a,9b = 11.9, J9a,8 = 2.5 Hz, 9a-H), 3.79–3.68 (5H,
overlapping, N(CH2CH2)2O and 4-H), 3.61 (1H, dd, J9b,9a =
11.9, J9b,8 = 6.6 Hz, 9b-H), 3.56 (1H, d, J7,8 = 9.4 Hz, 7-H),
2.88–2.81 (2H, overlapping, N(CH2CH2)2O), 2.69–2.62 (2H,
overlapping, N(CH2CH2)2O);
13C NMR (D2O) δ 169.8 (C-1),
159.9 (t, JC,F = 26 Hz, COCF2CF2CF2), 150.6 (C-2),
120.0–111.5 (3C, CF2CF2CF3), 104.0 (C-3), 75.8 (C-6), 70.6
(C-8), 69.3 (C-7), 67.2 (2C, N(CH2CH2)2O), 63.8 (C-9), 62.4
(C-4), 49.0 (2C, N(CH2CH2)2O), 45.0 (C-5); MS (ESI negative)
m/z 513.2 [M − H]−.
2,6-anhydro-5-(2,2,3,3,4,4,4-heptaﬂuorobutanamido)-4-(piper-
idin-1-yl)-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enoic acid
(7c). Starting from the protected glycal 14c (65 mg, 0.10 mmol)
the free glycal 7c (44 mg, 85%) was obtained, as a white solid:
m.p. 188–190 °C; [α]20D + 24.9 (c 1 in CH3OH); (Found: C,
42.10; H, 4.50; N, 5.43; Calc. for: C18H23F7N2O7 C, 42.19; H,
4.52; N, 5.47%); 1H NMR (D2O) δ 5.80 (1H, d, J3,4 = 1.6 Hz,
3-H), 4.74 (1H, under water signal, 5-H), 4.40 (1H, d app, J6,5 =
10.0 Hz, 6-H), 4.22 (1H, br s, 4-H), 3.96 (1H, m, 8-H), 3.88
(1H, dd, J9a,9b = 11.9, J9a,8 = 1.8 Hz, 9a-H), 3.62 (1H, dd, J9b,9a
= 11.9, J9b,8 = 6.4 Hz, 9b-H), 3.55 (1H, d app., J7,8 = 9.2 Hz, 7-
H), 3.30–3.23 (2H, overlapping, N(CH2CH2)2CH2), 3.23–3.15
(2H, overlapping, N(CH2CH2)2CH2), 1.93–1.47 (6H, overlap-
ping, N(CH2CH2)2CH2);
13C NMR (D2O) δ 168.3 (C-1), 159.8
(t, JC,F = 26 Hz, COCF2CF2CF3), 152.4 (C-2), 119.5–107.4 (3C,
CF2CF2CF3), 99.3 (C-3), 75.4 (C-6), 69.8 (C-8), 68.3 (C-7),
63.3 (C-9), 63.1 (C-4), 50.2 (2C, N(CH2CH2)2CH2), 43.3 (C-5),
23.7 (2C, N(CH2CH2)2CH2), 22.0 (1C, N(CH2CH2)2CH2); MS
(ESI negative) m/z 511.2 [M − H]−.
Biological assays
Sialidase enzyme assay. Vibrio cholerae sialidase inhibition
activity was performed essentially according to Venerando
et al.,36,37 but using the ﬂuorescent artiﬁcial substrate 4-methyl-
umbelliferyl N-acetylneuraminic acid (4-MU-Neu5Ac).
Brieﬂy, the incubation mixture (ﬁnal volume of 100 μL) con-
tained 0.1–0.5 mU of Vibrio cholerae sialidase, various amounts
of 4-MU-Neu5Ac, 80 μg of bovine serum albumin (BSA),
2.5 μmol of Tris/HCl buffer (pH 6.9). After incubation at 37 °C
for 5–10 min, the reactions were stopped by the addition of
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1.5 mL of 0.2 M glycine buffered with NaOH at pH 10.2, and
sialidase activity was determined by spectroﬂuorometric
measurement of the 4-methylumbelliferone released (λ excitation
365 nm, λ emission 445 nm). One unit of sialidase was deﬁned
as the amount releasing 1 μmol of N-acetylneuraminic acid
min−1 at 37 °C. Km and apparent Vmax values were determined
by the method of Lineweaver and Burk using ﬁve different
4-MU-Neu5Ac concentrations. To measure the inhibitory con-
stants Ki, typical Vo/[S] experiments were carried out in the pres-
ence of three different inhibitor concentrations. To obtain a value
for Ki, the kinetic data were ﬁtted to the standard equation for
competitive inhibition.
The results are the mean of at least two experiments carried
out in triplicate.
In vitro screening of glycals 6a–d and 7a–d for their potential
antiviral activities. The test was that routinely used in the
Department of one of the authors (R. M.). Brieﬂy, 50 μL of
serial 2-fold dilutions of each glycal were incubated overnight
with 100 μL of MDCK cells giving a ﬁnal cell count of 30 000
cells per well in a 96-well microtitre plate (Nunc A/S Roskilde,
Denmark), for the drug to equilibrate with the cells. 50 μL of
virus at a concentration of 100 50% tissue culture infectivity
dose (TCID50) was added to each well and the plate incubated
at 37 °C in 5% CO2 for 2 days. Viral replication was assessed by
two methods: real-time RT-PCR using the described proto-
col38,39 was carried out on nucleic acid extracted from the super-
natant of the culture, using the Roche Lightcycler system (Roche
Diagnostics, Mannheim, Germany); FITC-labeled anti-nucleo-
protein monoclonal antibody (Chemicon International, Teme-
cula, CA) was used to stain the remaining cell monolayer and
viewed under an ultraviolet light microscope. Controls consisting
of virus and cell only, cell only, virus only and serial 2-fold
dilution of amantadine in place of substance in study were
included in each plate. Cytotoxicity of the drugs was also
assessed at all concentrations used in the antiviral assay.
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